{
  "query": "suzetrigine",
  "search_date": "2025-03-23T13:22:51.934388",
  "metadata": {
    "count": "2",
    "retmax": "2",
    "retstart": "0",
    "querykey": "1",
    "webenv": "MCID_67e00b28da8822cd930f4d48",
    "idlist": [
      "11914629",
      "11570969"
    ],
    "translationset": [],
    "translationstack": [
      {
        "term": "suzetrigine[All Fields]",
        "field": "All Fields",
        "count": "4",
        "explode": "N"
      },
      "GROUP"
    ],
    "querytranslation": "suzetrigine[All Fields]"
  },
  "articles": [
    {
      "pmcid": "11914629",
      "title": "Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective NaV1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain",
      "first_author": "Osteen JD",
      "co_authors": [
        "Immani S",
        "Tapley TL",
        "Indersmitten T",
        "Hurst NW",
        "Healey T",
        "Aertgeerts K",
        "Negulescu PA",
        "Lechner SM"
      ],
      "journal": "Pain and Therapy",
      "publication_date": "2025 Jan 8",
      "abstract": "Abstract not available",
      "full_text_links": [
        "https://doi.org/10.1007/s40122-024-00697-0",
        "https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC11914629"
      ],
      "doi": "10.1007/s40122-024-00697-0"
    },
    {
      "pmcid": "11570969",
      "title": "Sodium channels Nav1.7, Nav1.8 and pain; two distinct mechanisms for Nav1.7 null analgesia",
      "first_author": "Iseppon F",
      "co_authors": [
        "Kanellopoulos AH",
        "Tian N",
        "Zhou J",
        "Caan G",
        "Chiozzi R",
        "Thalassinos K",
        "\u00c7ubuk C",
        "Lewis MJ",
        "Cox JJ",
        "Zhao J",
        "Woods CG",
        "Wood JN"
      ],
      "journal": "Neurobiology of Pain",
      "publication_date": "2024 Oct 11",
      "abstract": "Highlights &#x2022; Distinct mechanisms of analgesia occur in embryonic and adult SCN9A Nav1.7 null mutants. &#x2022; Embryonic null mutants lose nociceptor neurotransmitter release through an endogenous opioid regulatory system. &#x2022; Adult gene deletion results in loss of excitability with no role for the opioid system. &#x2022; Embryonic null mice are viable because of compensatory expression of Nav1.1 and Nav1.2 in sensory neurons. &#x2022; Nav1.7 targeted drugs act on both pain and the autonomic nervous system to produce unacceptable side effects.",
      "full_text_links": [
        "https://doi.org/10.1016/j.ynpai.2024.100168",
        "https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC11570969"
      ],
      "doi": "10.1016/j.ynpai.2024.100168"
    }
  ]
}